Accro Bioscience’s $50m round signals growing interest in targeted IBD immunology
IBD needs safer oral options. Accro’s $50 million raise puts RIPK2 inhibition closer to a decisive clinical test.
Pharma & Biotech
IBD needs safer oral options. Accro’s $50 million raise puts RIPK2 inhibition closer to a decisive clinical test.